Optimal use of antimalarials in treating cutaneous lupus erythematosus.
about
A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adultsNew concepts in antimalarial use and mode of action in dermatology.Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users.Long-term response to hydroxychloroquine in patients with discoid lupus erythematosus.Acquired facial lipoatrophy: pathogenesis and therapeutic options.Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment.Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches.Transient ischemic attack and stroke in systemic lupus erythematosus.Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases.Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases.Chloroquine-induced subacute paranoid-like disorder as a complication of dermatological treatment.Hard palate hyperpigmentation secondary to chronic chloroquine therapy: report of five cases.Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study.Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus.Hyperpigmentation of hard palate induced by chloroquine therapy.Beneficial effect of hydroxychloroquine on cutaneous vasculitis in a Japanese patient with systemic lupus erythematosus.
P2860
Q28475036-E45C5C55-7911-43B3-ACD2-6874E1FF8271Q34007922-12BE3D9E-3D67-48A2-B921-4C1E10E6483EQ34315879-06446079-5D3E-4715-A7CD-7602A150FD82Q34650392-951B94C4-462A-471A-BFA7-B56525BF5220Q35620537-DFC80249-65EE-465C-AA78-253C06999B26Q35764302-D46913F2-7E65-47EF-ABC2-C5CE1ECD5458Q35803068-BE826545-7B64-4588-88C9-84597449288DQ36793158-B6853CB3-F3F8-4144-8436-DCB21D2071C8Q38149851-5AC5A2B6-8799-4472-AC4D-DE88DEE45E6DQ38360827-D44FB662-6141-4F21-8745-5F18D25E5123Q38720050-68483C4B-2A57-46F4-A2B0-E58B99F14EF2Q41913974-8B517FBD-42F2-4158-AE32-761FAEB8B3E7Q41925305-49D04E57-F16C-45F1-8384-2D6ED5276CA4Q41930905-9B29FF6B-B4E4-40B8-8CB2-2C408FA7943DQ41943280-FF71C3F5-091C-4D69-80D7-50618BDDCC10Q49239104-50D2BCB5-0A6B-4218-A844-E18C66F6C8E7Q50229972-9F390156-98C8-492A-99A2-17D4E7F7F888
P2860
Optimal use of antimalarials in treating cutaneous lupus erythematosus.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Optimal use of antimalarials in treating cutaneous lupus erythematosus.
@ast
Optimal use of antimalarials in treating cutaneous lupus erythematosus.
@en
type
label
Optimal use of antimalarials in treating cutaneous lupus erythematosus.
@ast
Optimal use of antimalarials in treating cutaneous lupus erythematosus.
@en
prefLabel
Optimal use of antimalarials in treating cutaneous lupus erythematosus.
@ast
Optimal use of antimalarials in treating cutaneous lupus erythematosus.
@en
P1476
Optimal use of antimalarials in treating cutaneous lupus erythematosus.
@en
P2093
Anna Wozniacka
Daniel P McCauliffe
P356
10.2165/00128071-200506010-00001
P577
2005-01-01T00:00:00Z
P6179
1046605307